What is Axithra?
Based in Ghent, Belgium, Axithra operates within the dynamic medtech sector, focusing on the development and provision of therapeutic drug monitoring systems. These systems are crucial for optimizing patient treatment by ensuring medication efficacy and minimizing adverse effects. The company's commitment to advancing healthcare through innovative technology positions it as a key player in its niche market. The substantial capital infusion indicates strong market confidence in Axithra's technological advancements and its potential to disrupt traditional healthcare monitoring paradigms.
How much funding has Axithra raised?
Axithra has raised a total of $10.7M across 1 funding round:
Angel/Seed
$10.7M
Angel/Seed (2023): $10.7M with participation from QBIC, Kurma Partners, and WerfenLife
Key Investors in Axithra
QBIC
Qbic is an inter-university venture capital fund focusing on the transformation of technological breakthroughs into sustainable businesses, particularly supporting deeptech, software, biotech, and medtech sectors.
Kurma Partners
Kurma Partners is a European venture capital firm specializing in healthcare and biotechnology, providing capital from pre-seed to growth stages for innovative companies and academic research projects.
WerfenLife
Werfen is a Spain-headquartered manufacturer of in-vitro diagnostic equipment and supplies, established in 1966.
What's next for Axithra?
The recent major strategic investment signals Axithra's transition into a scaling phase, likely aimed at expanding its product reach, enhancing research and development capabilities, and potentially entering new geographical markets. With a total funding amount of $10.7M, the company is well-positioned to pursue aggressive growth strategies. Future developments may include further technological integration, strategic partnerships within the healthcare ecosystem, and the commercialization of its advanced therapeutic drug monitoring solutions to address unmet medical needs.
See full Axithra company page
